Morgan Stanley has issued a research report highlighting a global strategic collaboration between Hengrui Pharma and Bristol Myers Squibb, covering 13 pre-clinical assets with a total transaction value of $15.2 billion. The deal includes a $600 million upfront payment, annual payments totaling $350 million between 2027 and 2028, up to $14.3 billion in milestone payments, and tiered sales royalties. The firm maintains Hengrui as its top pick in China's healthcare sector, assigning an "Overweight" rating with an H-share target price of HK$92. According to the report, this strategic partnership, encompassing multiple formats and asset modalities, further validates Hengrui Pharma's early-stage R&D platform and enhanced global capabilities. Beyond the near-term cash benefits, the bilateral collaboration structure and options for co-development and commercialization are expected to accelerate Hengrui's globalization efforts and generate commercial synergies for its expanding immunology portfolio in the Chinese market.